Phase III Trial Comparing Methotrexate and Cetuximab in First-line Treatment of Recurrent and/or Metastatic Squamous Cell Head and Neck Cancer

NCT01884623 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

82

Enrollment

OTHER

Sponsor class

Conditions

Head Neck Cancer Squamous Cell Recurrent

Interventions

DRUG: Cetuximab
DRUG: Methotrexate

Sponsor

Gustave Roussy, Cancer Campus, Grand Paris

Collaborators

[object Object]
[object Object]
[object Object]